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Abstract: While molecular testing with real-time polymerase chain reaction (RT-PCR) remains the
gold-standard test for COVID-19 diagnosis and screening, more rapid or affordable molecular
and antigen testing options have been developed. More affordable, point-of-care antigen testing,
despite being less sensitive compared to molecular assays, might be preferable for wider screening
initiatives. Simple laboratory, imaging and clinical parameters could facilitate prognostication and
triage. This comprehensive review summarises current evidence on the diagnostic, screening and
prognostic tests for COVID-19.
Keywords: SARS-CoV2; COVID-19; coronavirus; diagnosis; screening; prognosis; PCR;
CRISP; immunoglobulin
1. Introduction
Declared a pandemic in March 2019, COVID-19, which is caused by the novel se-
vere acute respiratory coronavirus 2 (SARS-CoV-2) has caused not only significant global
morbidity (>160 million cases) and mortality (>3.4 million deaths), but also disruption to
society and economies [1–4]. The true incidence of COVID-19 is likely to have been under-
estimated, either due to individuals underreporting mild symptoms or inadequate testing.
Screening and diagnostic strategies for COVID-19 have varied worldwide according to
government policies, technology, funding, and data management capabilities. Even in
industrialised nations, uncertainties in strategy, regulatory hurdles and supply issues have
disrupted testing capabilities, possibly contributing to worsening spread of SARS-CoV2.
Standardisation and improvement of COVID-19 diagnostics, with more efficient detection
and treatment of cases, is likely to be beneficial to both industrialised and low-income
nations [5–7]. In this review, we address some of the key concerns regarding laboratory
and radiological screening, diagnosis and prognostication that have arisen during the
ongoing COVID-19 pandemic [8]. A detailed description of the characteristics of the
available screening and diagnostic assays and medical devices is beyond the scope of this
manuscript and can be found in the Joint Research Centre of the European Medicines
Agency/European Commission (https://covid-19-diagnostics.jrc.ec.europa.eu/devices,
accessed on 10 June 2021).
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2. Diagnostic Testing
Confirming diagnosis, starting treatment (where necessary) and initiation of social-
distancing measures are essential in the management of COVID-19. Numerous methods
are utilised for the laboratory diagnosis of viral infections, such as culture, viral nucleic acid
detection and serology (i.e., viral antigen or humoral responses) [9]. The most commonly
available tests are direct (detection of nucleic acids (i.e., viral genome) or antigens of the
virus) and indirect (assessment of serum antibody levels).
2.1. Direct Testing—Molecular Methods
Viral nucleic acid detection, directly detecting genetic material, is the gold stan-
dard in diagnostic virology [9]. Two commonly preferred nucleic acid-based detection
methodologies are available for the diagnosis of SARS-CoV-2. RT-PCR based methods
(real-time polymerase chain reaction (RT-PCR)) are routinely used for diagnosis, while high
throughput genome sequencing is used at an unprecedented rate for COVID-19 variants
surveillance [10].
RT-PCR has frequently been utilised in the detection of COVID-19 nucleic acids from
a number of sources such as posterior oropharyngeal saliva, throat and nasopharyngeal
swabs, sputum and bronchial fluid [11]. Moreover, in some cases the virus can be isolated
from blood, semen and faeces, even in the absence of a positive respiratory sample [12].
However, a recent systematic review concluded that RT-PCR tests from stool, urine, and
plasma were less sensitive than respiratory samples [13].
In spite of RT-PCR being the benchmark for COVID-19 diagnosis, there is a potential
for false-negative results, which may be related to the viral load, sampling time or sampling
bias. RT-PCR tests typically provide a positive result if the specimen is collected 2–8 days
after the onset of the infection [14]. A meta-analysis, which assessed the accuracy of
COVID-19 tests and included 34 studies with 12,057 COVID-19 confirmed cases reported
false-negative RT-PCR rates between 2% and 29%. The reported sensitivity was 71-98%,
based on individuals with an initial negative RT-PCR being subsequently found to have
a positive one. COVID-19 diagnostic accuracy may be improved by combining results of
RT-PCR, imaging and serology screening [13].
Several other methods, namely, droplet digital PCR (ddPCR) and reverse transcription-
loop-mediated isothermal amplification (RT-LAMP), which detect SARS-CoV-2 RNA are
being also used to complement RT-PCR. Overall, ddPCR performs better than standard
RT-PCR for clinical diagnosis of SARS-CoV-2, reducing false-negative results, although
it is less thoroughly evaluated compared to the latter [15,16]. This is further highlighted
by evidence showing the ddPCR-based can effectively detect SARS-CoV-2 genome in
symptomatic cases with a negative standard RT-PCR [17]. A recently published study
reported that combining RT-PCR with ddPCR improves the sensitivity from 40% (95% CI:
27–55%) to 94% (95% CI: 83–99%) without limiting the specificity, which remains 100%
(95% CI: 48–100%), leading to an overall increase in the diagnostic accuracy from 47% (95%
CI: 33–60%) to 95% (95% CI: 84–99%) [16].
Rapid diagnosis of COVID-19 is important, and some methods provide a result in less
than an hour. RT-LAMP detects SARS-CoV-2 RNA in approximately 30 min with good
correlation to the conventional RT-PCR, allowing for rapid delivery of results to patients
both in the hospital and community settings [18]. RT-LAMP has been reported to have
high sensitivity and specificity, operational simplicity and low cost [19].
Data on analytical performance (i.e., sensitivity, specificity, lower limits of detection
(LOD), etc.) for all commercially available molecular assays are provided by FIND (a global
alliance for diagnostics, which seeks to ensure equitable access to reliable diagnosis around
the world) and can be assessed in the following directory, which is regularly updated
(https://www.finddx.org/test-directory/, accessed on 10 June 2021).
Alternative approaches based on combinations of isothermal amplification and clus-
tered regularly interspaced short palindromic repeats (CRISPR) such as the SHERLOCK
(specific high-sensitivity enzymatic reporter unlocking) technique reduce dependence on
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RT-qPCR equipment [20]. SHERLOCK was found to be 98.5% specific and 93.1% sensitive
with a lateral-flow readout [20]. The fluorescence readout was 100% specific and 96%
sensitive for the full range of viral load in the clinical samples. In 380 SARS-CoV-2-negative
samples obtained prior to surgery, SHERLOCK matched quantitative PCR with reverse
transcription in 100% of cases [21,22]. However, data on RT-LAMP and CRISPR are signifi-
cantly more limited than on PCR methods. Further validation is required. A comparison of
the molecular-based direct diagnostic methods is shown in Table 1.
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Table 1. Comparison of molecular diagnostic tests.
Method Biomarker Description Type of Clinical Sample Operating Temperature Assay Time Advantages Limitations
RT PCR Nucleic acid(SARS-CoV-2 RNA)
– Regular real time
PCR
– Gold Standard





– Risk of cross
contamination.
ddPCR Nucleic acid(SARS-CoV-2 RNA)





Throat swab Thermal cycling 1 h
– High sensitivity in low
viral load specimens





RT-LAMP Nucleic acid(SARS-CoV-2 RNA)
– Isothermal





Throat swab 30–65 ◦C 30 min
– High sensitivity and
specificity.Uses simple
instruments.
– Does not require thermal
cycling (and is therefore
rapid and affordable).
– Uses simple instruments.
– Challenges in generating
sequence specific primers.
However, commercially
assays are now available.
– An internal PCR inhibition
control cannot be included,
and therefore duplication










Nasopharyngeal swabs <1 h
– Low cost
– Higher sensitivity
– Uses simple instruments.
– Cas13 does not
catalytically activate when
there are two or more












– C62 ◦C for RT
LAMP




– Easy to implement
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Efficient testing in COVID-19 is important but the time in which results are generated
varies significantly, not only with choice of molecular tests, but also due to an array of
factors not limited to transportation, processing and reporting [8]. Speed of results could
certainly be improved with better test-to-laboratory and results to clinician pathways,
but improving the efficiency of these steps is not always straightforward. The COVID-19
pandemic has however highlighted the importance of low-cost rapid point of care (POC)
virology diagnostics [19].
Of the hundreds of SARS-CoV-2 diagnostic test assays under development or in use,
syndromic testing is of particular interest in tackling the pandemic. This is the process
of simultaneously targeting and detecting multiple pathogens that cause similar signs
and symptoms, especially during the winter season when multiple different viruses could
be circulating.
Syndromic respiratory testing, such as the Multiplex RT-PCR tests that detect multiple
respiratory viruses in the same specimen including SARS-CoV-2, influenza, and 21 other
common respiratory viral and bacterial pathogens have huge potential to streamline
diagnosis and early disease specific treatment [23,24]. An added benefit is the speed in
which syndromic tests return.
There is still a role for single COVID-19 tests, when pre-test probability is high or
contact tracing is required. On the over hand, syndromic tests are extremely useful when
symptoms are non-specific, and the list of possible diagnoses is long. Similarly, diagnostic
accuracy is more important in patients with moderate or severe disease, as SARS-CoV2
management (dexamethasone, anti-virals, immunomodulatory treatments), differs signifi-
cantly to that of alternative conditions.
2.2. Direct Testing—Antigen Testing
Antigen tests can detect the presence of SARS-CoV-2 viral proteins in nasal or pha-
ryngeal swabs and saliva. Most are lateral-flow chromatographic immunoassays (point
of care, rapid detection) or chemiluminescence immunoassays (laboratory-based). Al-
though direct antigen tests are increasingly used, the diagnostic accuracy of these tests is
lower in comparison with that of RT-PCR [25]. There are some concerns regarding their
specificity, since they may cross-react with other coronaviruses, but the main issue is their
sensitivity [26]. The sensitivity of such panels ranges between 34% and 88%, based on the
findings of a Cochrane systematic review [25,27]. Therefore, despite the higher accuracy
of positive results, negative results should be treated more cautiously. Their diagnostic
accuracy is greatest in symptomatic patients, when the viral load in the nasopharynx is
higher, enabling early diagnosis, triage and treatment [28]. The optimum timing of testing
can vary (within 5, 7 and 12 days from symptom onset) [29]. Therefore, the advantages
of point of care tests, with rapid identification and isolation of cases, at a lower cost to
RT-PCR tests, may perhaps be limited to some extent by the poor sensitivity they offer,
especially in asymptomatic or pre-symptomatic individuals. Despite these limitations,
the main advantages of antigen tests are speed (usually around 5–30 min compared with
hours for PCR-based techniques), ease of interpretation and the limited technical skill and
infrastructure required. This is particularly important for resource-limited settings [30]. In
balance, it has been proposed that rapid and real-time viral antigen detection assays have
been shown to be more useful in controlling the spread of the infection than more sensitive,
but more expensive tests with more prolonged test time, such as the molecular tests [14].
2.3. Indirect Testing
Serological testing is an alternative means of diagnosing COVID-19. Whereas in most
infections the IgM response precedes IgG, the distinction in COVID-19 (where both can
be detected in the initial weeks) is less clear. This explains the similarities in the pooled
sensitivity of both IgM and IgG in the early weeks of COVID-19 infection—33% and 23%
at one week and 73% and 68% at two weeks, respectively [31]. At three to four weeks the
picture begins to change, with IgG or total antibody tests providing the greatest sensitivity
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(low false-negative results) and specificity (low false-positive results) compared to other
antibody types [31].
Several methods have been proposed for accurate assessment of IgG and IgM antibod-
ies such as ELISA, lateral flow immunoassay-based Kits (LFIA) and chemiluminescence
immunoassay-based Kits (CLIA) [32–34].
In a meta-analysis of COVID-19 serology tests that included 40 studies, the pooled
sensitivity of IgG or IgM ELISA was 84.3% (95% confidence interval, 75.6% to 90.9%), for
LFIAs it was 66.0% (49.3% to 79.3%), and for CLIAs it was 97.8% (46.2% to 100%). Among
LFIAs, the pooled sensitivity of commercial kits was 65.0% (49.0% to 78.2%), which was
lower than that of non-commercial tests, 88.2% (83.6% to 91.3%).
Sensitivity was higher from three weeks after symptom onset (ranging from 69.9%
to 98.9%) compared to within the first week (13.4% to 50.3%) [35]. The specificity of
the evaluated assays was less variable and ranged between 96.6% to 99.7%. However,
heterogeneity was observed in all analyses and methodological issues, such as patients’
selection bias, were identified across most of the studies included in this meta-analysis [36].
False-positive serological testing results have been associated with the presence of
other viral infections (cytomegalovirus) or autoimmune diseases (such as scleroderma or
systemic lupus erythematosus) [37,38].
2.4. Conventional Diagnostic Approaches
2.4.1. Clinical Presentation
The most frequent symptoms of COVID-19 at presentation are cough (67.8%), fever
(43.8%), and breathlessness (18.7%) [39]. Signs and symptoms in COVID-19 are however not
specific and are often indistinguishable from those of other respiratory viruses. Even lack of
smell or loss of taste are not specific for COVID-19 and can be easily confused with almost
any other viral respiratory disease, which may also be endemic during winter period.
Clinical symptoms are not a reliable way of diagnosing COVID-19 patients except
for patients with recent COVID-19 contact. Where there is significant transmission within
a region or country, monitoring the number of healthcare consultations for COVID-19
compatible symptoms and establishing a diagnosis (including alternatives such as influenza
and acute bacterial respiratory infection) helps identify further cases for testing (robust
syndromic surveillance).
2.4.2. Pulse Oximetry
Pulse oximetry is a simple and accessible tool for screening and continuous monitoring
of patients with COVID-19. The target oxygen saturation range for patients with COVID-
19 without comorbidities such as chronic obstructive pulmonary disease (COPD) is 92–
96% [3,4,40]. The test is particularly useful in COVID-19 as patients can have severe
hypoxemia in the absence of dyspnoea, sometimes referred to as “silent hypoxemia”. Home
monitoring of patients with COVID-19, with patients only being admitted to hospital if
the oxygen saturations decline below 92%, has been a valuable tool to reduce admissions
and provide safe monitoring in the community [41,42]. Severe COVID-19 is suggested
by oxygen saturation levels <92% (<88% in COPD) on room air, while in the absence of
hypoxaemia most patients can be monitored at home [43].
Home SpO2 <92% was linked to a greater risk of intensive care unit admission, acute
respiratory distress syndrome (ARDS) and septic shock. Therefore, a SpO2 cutoff of 92%
was found to be a useful an indicator for readmission [44].
Initial oxygen saturation measured by ambulance staff in patients with COVID-
19 patients correlate well with short-term (30-day) patient mortality or ICU admission.
Even small deviations in oxygen saturation of 1–2% below 96% confer an increased mortal-
ity risk [45].
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2.4.3. Hematological Evaluation
Thrombocytopenia, leukopenia and neutropenia can all be seen in COVID-19 dis-
ease [39,46]. Lymphopenia (89.2%) is the most common finding on a full blood count
(FBC), followed by neutrophilia (74.3%), and thrombocytopenia (24.3%) [47]. Lymphopenia
and eosinopenia were also associated with severe disease and mortality and they were
identified in 77.6% and 81.2% of non-survivors [48–50]. Although FBC patterns cannot be
used for diagnosis alone, they can assist in triage and prognostication.
Several indices based on FBC variables have been developed to help guide COVID-19
diagnosis, prognostication and triage (Table 2). Systemic inflammation index (SII) is a
biomarker predictive of in-hospital mortality and the development of ARDS [51].
Table 2. Inflammation indices related to mortality in COVID-19 [49].





Cut off point >1835 sensitivity 55%
specificity 75%
SIRI neutrophil ×monocyte/lymphocyte
Cut off point >2.93 sensitivity 59%
specificity 74%
AISI neutrophil × platelet ×monocyte/lymphocyte
Cut off point>798 sensitivity 59%
specificity 72%
NLR neutrophil/lymphocyte ratio Cut off point >15.2 sensitivity 38%specificity 97%
NLPR neutrophil/(lymphocyte ×platelet)
Cut off point >0.019 sensitivity 66%
specificity 75%
dNLR neutrophils/(white bloodcells -neutrophils)
Cut off point >6.2 sensitivity 52%
specificity 85%
AISI—index of systemic inflammation, NLR—neutrophil to lymphocyte ratio, NLPR—neutrophil to lympho-
cyte × platelet ratio, NLR—neutrophil to lymphocyte ratio, SII—systemic inflammation index, SIRI—systemic
inflammation response index.
Non-survivors had significantly higher index of systemic inflammation (AISI), derived
neutrophil to lymphocyte ratio (dNLR), neutrophil to lymphocyte × platelet ratio (NLPR),
neutrophil to lymphocyte ratio (NLR), systemic inflammation index (SII), and systemic
inflammation response index (SIRI) values when compared to survivors. All of these
indices are calculated based on FBC and their comparison is presented in Table 2. Kaplan–
Meier survival curves showed significantly lower survival in patients with higher AISI,
dNLR, MLR, NLPR, NLR, SII, and SIRI. However, after adjusting for confounders, SII was
best at predicting survival [52].
Some of these inflammatory markers may also have a diagnostic value. Lymphopenia
is suggestive of COVID-19 in patients with consistent clinical presentation and imaging.
Moreover, it seems that most patients have a high NLR of >5 (94.5%), high SII index of
>500 (89.2%), increased C-reactive protein (100%) and high level of IL6 (>10 pg/mL) [47].
Since the pathogenesis of COVID-19 is tightly linked to pro-inflammatory state and
cytokine storm, several interleukins (IL) have been evaluated as diagnostic and prognos-
tic markers. Baseline changes in IL-6, IL-10 and their ratio may be a good prognostic
marker [53]. Studies have shown that IL-6 correlates with clinical outcomes, such as mor-
tality and respiratory failure better than laboratory alternatives such as CRP, ferritin and
liver enzymes [54,55]. A comparison of the inflammatory markers is presented in Table 3.
Life 2021, 11, 561 8 of 14
Table 3. Inflammatory biomarkers.
Marker/Score Applicability Reference
CRP
Detection of severe/critical illness: Threshold:
41.4; Sensitivity: 90.5%; specificity: 77.6%;




In-hospital mortality: Threshold: 37.65 pg/mL;
Sensitivity: 91.7%; Specificity: 95.7%.
Rise in IL-6 from presentation to day 4 was
predictive of a more severe clinical outcome (OR
1.14, 95% CI 1.07–1.21, per 10 units increase)
[53,57]
IL-6:IL-10 ratio
Rise in IL-6/IL-10 ratio from presentation to day
4 was predictive of increased risk of a more
severe clinical outcome (OR 1.28, 95% CI
1.17–1.40, per 0.1 units increase)
[53]
Dublin-Boston score
Calculated by multiplying the day 0 to day 4
change in IL-6:IL-10 ratio by two, rounding to
whole numbers, and then restricting the score to
a 5-point scale ranging from −2 to 2. Rise in the
Dublin-Boston score was predictive of a more
severe outcome (OR 5.62, 95% CI −3.22–9.81, p =
1.2 × 10−9, per 1 point increase)
[53]
IL—interleukin, CRP—C-reactive peptide.
The concept of cytokine storm has been recently reappraised. A recent systematic
review and meta-analysis based on 25 studies has reviewed the role of IL-6 in patients with
severe or critical disease. Patients with COVID-19 (n = 1245 patients) were compared to
patient with sepsis (n = 5320), cytokine release syndrome (n = 72), and acute respiratory
distress syndrome unrelated to COVID-19 (n = 2767). Mean interleukin-6 concentrations
were nearly 100 times greater in patients with cytokine release syndrome, 27 times higher in
patients with septic shock, and 12 times higher in patients with ARDS unrelated to COVID-
19 [58]. This data does not support the concept of a COVID-19-induced organ dysfunction.
Serum levels of IL-6 and IL-10 are also strong predictors of disease progression and
severity [59]. Being inexpensive, they can be performed on arrival to hospitals or care
centers with minimum facilities. Using these tests, earlier identification of patients at risk
of severe disease may be possible.
2.4.4. Coagulation
Coagulation dysfunction is a risk factor for adverse outcomes in COVID-19 and
should be carefully considered in caring for patients [60]. Thrombocytopenia is detected
in more than a half of the patients and its incidence varies according to disease severity.
It is typically mild (100–150 × 109/L) [61]. Although non-diagnostic, platelet counts and
coagulation markers provide valuable information.
In one study, coagulation function in COVID-19 was assessed with thrombin- an-
tithrombin complex (TAT), α2-plasmininhibitor-plasmin complex (PIC), thrombomodulin
(TM), t-PA/PAI-1 complex (t-PAIC), prothrombin time (PT), international normalised ratio
(INR), activated partial thromboplastin time (APTT), fibrinogen (FIB), thrombin time (TT),
D-Dimer (DD), and platelet (PLT). The levels of TAT, PIC, TM, t-PAIC, PT, INR, FIB, and
DD in COVID-19 patients were higher than healthy controls (p < 0.05) and in those with
thrombotic disease than without thrombotic disease (p < 0.05). Patients with thrombotic
disease had a higher case-fatality (p < 0.05). TAT, PIC, TM, t-PAIC, PT, INR, APTT, FIB,
DD, and PLT also correlated with disease severity. T-PAIC and DD were independent
risk factors for death and accurately predicted COVID-19 mortality risk [62–64]. Since a
coagulation panel is a standard procedure, it is useful to assess several parameters that can
indicate severity of the disease and a risk of thrombosis (Table 4).
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Table 4. Coagulation parameters helpful in COVID-19 triage.
Tests Impact Reference
DD In-hospital mortality. Threshold: 2.0 µg/mL;Sensitivity: 92.3%; Specificity: 83.3%. [63]
t-PAIC In-hospital mortality. Threshold: 20.6 ng/mL;Sensitivity: 90.0%; Specificity: 91.2%. [64]
PT
In-hospital mortality. Prolonged prothrombin
time was predictive of mortality (OR: 2.19, 95%
CI: 1.29-3.73).
[65]
FIB Development of ARDS. Threshold: 617 mg/dL;Sensitivity: 76%; Specificity: 79%. [66]
PLT
Mortality: Elevating platelet counts are
predictive of decreased mortality. 50 × 109/L
increment increase in platelets was associated
with 40% decrease in mortality. Among
hospitalised patients, the platelet trajectory
(increase or decrease) during hospital stay, was
associated with decreased or increased mortality,
respectively.
[67]
ISTH criteria of DIC
DIC is strongly associated with mortality. 71.4%
of non-survivors fulfilled the ISTH criteria for
overt DIC (≥5 points) in the later stages of
coronavirus pneumonia, while the respective
proportion among survivors was 0.6%.
[68]
TAT—thrombin-antithrombin complex, PIC—α2-plasmininhibitor-plasmin Complex, t-PAIC—t-PA/PAI-1 Com-
plex, PT—prothrombin time, FIB—fibrinogen, DD—D-Dimer, PLT—platelet, ISTH—International Society on
Thrombosis and Haemostasis, DIC—disseminated intravascular coagulation.
2.4.5. Comorbidities
Comorbid conditions often present a risk factor for adverse outcomes in infectious
diseases. Numerous comorbidities have been correlated with adverse outcomes of COVID-
19. However, COVID-19 outcomes are strongly correlated with age and gender, and most
studies evaluating prognostic factors have not adequately accounted for these confounders.
However, a recent meta-analysis using age and gender adjusted data confirmed strong
associations between co-existing diseases such as chronic heart failure, ischemic heart
disease, chronic obstructive pulmonary disease, diabetes mellitus, hypertension, malig-
nancy, end-stage renal disease, dementia and obesity and increased COVID-19 related
mortality [69].
A retrospective cohort study of 31,461 adults with COVID-19 from 24 healthcare
organisations in the US demonstrated a high burden of comorbidities. Those most com-
monly listed were chronic obstructive pulmonary disease (COPD) (17.5%) and type 2
diabetes (15%). Using multivariate logistic regression analysis, higher odds of mortality
with COVID-19 was seen across a range of conditions including dementia (OR 1.29), my-
ocardial infarction (OR 1.97), cardiac failure (OR 1.42), COPD (OR 1.24), moderate to severe
liver disease (OR 2.62), renal disease (OR 2.13) and metastatic malignancy (OR 1.70) [70].
This study highlights the need to have low clinical suspicion of COVID-19 in patients
with multiple co-morbidities and to screen for moderate to severe disease early in the
disease course.
Charlson comorbidity index (CCI), Elixhauser (ECI), and age- and smoking-adjusted
Charlson (ASCCI) and Elixhauser (ASECI) comorbidity indices have also been used to
predict COVID-19 outcomes. Patients with higher indices had a significantly longer time
of hospitalisation (more than 24 days). CCI score >2 had a sensitivity of 79% and specificity
of 71.9% for predicting longer time of hospitalisation, while ASCCI >3 had a sensitivity of
57.9% and specificity of 96.9%, and ASECI score >5 had a specificity of 57.9% and sensitivity
of 90,6%. Using these scores, it may be possible to identify cases with potential for severe
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disease, and therefore a poorer prognosis earlier, allowing better treatment planning and
communication [71].
Per point increase of CCI score is associated with an increased mortality risk of 16%.
A higher mean CCI score is also significantly associated with mortality and disease severity.
CCI score should be utilised for risk stratifications of hospitalised COVID-19 patients [72].
Vitamin D deficiency represents a well-established modifiable risk factor for severe
COVID-19 disease and COVID-19 related mortality [73]. There is preliminary evidence
suggesting that Vitamin D replacement could protect from COVID-19 contraction or ad-
verse outcomes [73,74].
On the other hand, other comorbidities, such as asthma [75–77], urticaria and erythema
nodosum [78] have been associated with decreased risk of adverse COVID-19 outcome.
However, these diseases often affect younger people, who are anyway less prone to COVID-
19 adverse outcomes, and therefore, the observed protective effect might be the result
of confounding [69].
2.4.6. Diagnostic Nomogram
Comorbid conditions often present a risk factor for adverse outcomes in infectious dis-
eases. Numerous comorbidities have been correlated with adverse outcomes of COVID-19.
Several parameters such as older age, higher serum lactate dehydrogenase (LDH),
CRP, coefficient of variation of red blood cell distribution width (RDW), direct bilirubin
(DBIL), blood urea nitrogen (BUN), and lower albumin on admission have been correlated
with higher odds of severe COVID-19. Therefore, they were used to elaborate a prognostic
nomogram composed of seven features for early identification of patients at risk of exacerba-
tion to severe COVID-19. The generated nomogram was efficient for early identification of
severe COVID-19 in the training cohort (AUC 0.912 (95% CI 0.846–0.978), sensitivity 85.71%,
specificity 87.58%); and in the validation cohort (0.853 (0.790–0.916), 77.5%, 78.4%) [79].
This diagnostic nomogram is assessed based on the admission laboratory tests.
2.4.7. Imaging
A recent meta-analysis of 34 studies with 9339 patients with SARS-CoV-2 infection,
confirmed using RT-PCR alone or RT-PCR with another test, assessed the diagnostic
efficiency of chest X-ray (CXR), computed topography (CT) and ultrasound (USS). COVID-
19 was correctly diagnosed based on CT thorax in 89.9% of patients with COVID-19 and
incorrectly identified in 38% of patients who did not have COVID-19. The sensitivity
of CXR ranged between 57–89%, while false-positive results ranged between 11–89% of
patients without COVID-19. Finally, the sensitivity of lung ultrasound was 96%, while
the corresponding false-positive rate was 38%. These findings demonstrate that chest
imaging modalities are sensitive in identifying COVID-19 with lower respiratory tract
involvement, while their specificity is limited [80]. Interestingly, inter-rater agreement on
the interpretation of chest x-rays is moderate [81,82].
Pre-operative CT chest has been successfully and widely used as a screening tool for
COVID-19 in people undergoing surgical procedures during the pandemic [83].
3. Conclusions
Molecular testing with RT-PCR is the gold-standard not only for screening and diag-
nosis of COVID-19, but also to follow-up disease progression. However, more affordable,
direct antigen or indirect antibody COVID-19 tests, despite their more limited sensitivity,
might be more cost-effective screening modalities. Selection of the optimal strategies for
COVID-19 screening, diagnosis and prognostication amidst the pandemic is complex. Un-
fortunately, the vast costs associated with these processes during the pandemic limit equity
globally and national strategies need to be informed by best available evidence, but also
by economics. Prediction models based on simple laboratory tests, imaging and clinical
variables can facilitate cost-effective prognostication and triage.
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Further research is needed to develop accurate and affordable screening and diagnostic
strategies, as well as accurate prognostic tools to facilitate identification of patients at risk
of deterioration and resource allocation.
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